Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...